Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Rhythm Pharmaceuticals Inc (RYTM)

Rhythm Pharmaceuticals Inc (RYTM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,991,931
  • Shares Outstanding, K 66,736
  • Annual Sales, $ 130,130 K
  • Annual Income, $ -260,600 K
  • EBIT $ -186 M
  • EBITDA $ -185 M
  • 60-Month Beta 1.96
  • Price/Sales 51.65
  • Price/Cash Flow N/A
  • Price/Book 44.95

Options Overview Details

View History
  • Implied Volatility 52.36% (-47.14%)
  • Historical Volatility 57.22%
  • IV Percentile 50%
  • IV Rank 20.11%
  • IV High 112.19% on 07/08/25
  • IV Low 37.30% on 05/16/25
  • Expected Move (DTE 7) 6.82 (5.80%)
  • Put/Call Vol Ratio 0.07
  • Today's Volume 1,265
  • Volume Avg (30-Day) 405
  • Put/Call OI Ratio 0.56
  • Today's Open Interest 8,508
  • Open Int (30-Day) 7,089
  • Expected Range 110.80 to 124.44

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.79
  • Number of Estimates 12
  • High Estimate -0.51
  • Low Estimate -0.96
  • Prior Year -0.72
  • Growth Rate Est. (year over year) -9.72%

Price Performance

See More
Period Period Low Period High Performance
1-Month
95.46 +23.21%
on 11/14/25
122.20 -3.75%
on 12/11/25
+17.76 (+17.78%)
since 11/11/25
3-Month
94.39 +24.61%
on 09/15/25
122.20 -3.75%
on 12/11/25
+19.70 (+20.12%)
since 09/11/25
52-Week
45.90 +156.25%
on 04/07/25
122.20 -3.75%
on 12/11/25
+60.47 (+105.81%)
since 12/11/24

Most Recent Stories

More News
Rhythm Pharmaceuticals Announces Preliminary Data from Exploratory Phase 2 Trial that showed Setmelanotide Demonstrated Positive Efficacy Signal in Prader-Willi Syndrome

- - BMI and hyperphagia reductions have been observed in patients with PWS treated with setmelanotide at Month 3 (n=8) and Month 6 (n=5); 17 of 18 enrolled patients remain on therapy -- -- Promising...

RYTM : 117.62 (+12.26%)
Rhythm Pharmaceuticals to Announce Preliminary Data from Exploratory Phase 2 Trial Evaluating Setmelanotide in Prader-Willi Syndrome

BOSTON, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare...

RYTM : 117.62 (+12.26%)
Rhythm Pharmaceuticals Announces Presentation of Four Datasets at ObesityWeek® 2025

–  Phase 3 TRANSCEND trial data showed setmelanotide achieved significant BMI reductions in patients with acquired hypothalamic obesity on concomitant treatment with GLP-1 therapy – – Analysis...

RYTM : 117.62 (+12.26%)
Rhythm Pharmaceuticals Announces FDA Extension of Review Period for IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity

-- FDA sets updated PDUFA goal date of March 20, 2026 –  -- Company to hold conference today at 8:00 a.m. -- BOSTON, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq:...

RYTM : 117.62 (+12.26%)
Rhythm Pharmaceuticals Announces Public Reimbursement for IMCIVREE® (setmelanotide) in Canada in Five Provinces and Under the Federal Non-Insured Health Benefits Program

BOSTON, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare...

RYTM : 117.62 (+12.26%)
Rhythm Pharmaceuticals Reports Third Quarter 2025 Financial Results and Business Update

-- Third quarter 2025 net product revenue from global sales of IMCIVREE ®  (setmelanotide) of $51.3 million -- -- December 20, 2025 PDUFA goal date set for sNDA for setmelanotide in acquired...

RYTM : 117.62 (+12.26%)
Rhythm Pharmaceuticals to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025

BOSTON, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare...

RYTM : 117.62 (+12.26%)
Analysts’ Top Healthcare Picks: CVS Health (CVS), Rhythm Pharmaceuticals (RYTM)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on CVS Health (CVS – Research Report) and Rhythm Pharmaceuticals (RYTM – Research Report) with bullish...

CVS : 80.83 (+2.36%)
RYTM : 117.62 (+12.26%)
Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences

BOSTON, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare...

RYTM : 117.62 (+12.26%)
Rhythm Pharmaceuticals Reports Second Quarter 2025 Financial Results and Business Update

-- Second quarter 2025 net product revenue from global sales of IMCIVREE ®  (setmelanotide) of $48.5 million -- -- U.S. and EU regulatory submissions for setmelanotide in acquired hypothalamic...

RYTM : 117.62 (+12.26%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company. It focused on the development and commercialization of peptide therapeutics for the treatment of rare genetic deficiencies which result in life-threatening metabolic disorders. The Company's product candidate principally consists of setmelanotide,...

See More

Key Turning Points

3rd Resistance Point 134.08
2nd Resistance Point 128.14
1st Resistance Point 122.88
Last Price 117.62
1st Support Level 111.68
2nd Support Level 105.74
3rd Support Level 100.48

See More

52-Week High 122.20
Last Price 117.62
Fibonacci 61.8% 93.05
Fibonacci 50% 84.05
Fibonacci 38.2% 75.05
52-Week Low 45.90

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar